Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Export-focused...

    Export-focused domestic pharma companies need to step up regulatory compliance: Report

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-11T09:15:09+05:30  |  Updated On 11 July 2019 9:15 AM IST
    Export-focused domestic pharma companies need to step up regulatory compliance: Report

    Mumbai: The US-focused domestic pharma companies need to step up regulatory compliance over the next decade and need to invest in complex generics and innovative play, says a report.


    As the operating environment in the US has undergone a shift following a rising competition and increasing buying power of customers, product quality and uninterrupted supply have become focal points for commercial success, an India Ratings report said Wednesday.


    Read Also: India to step up pharmaceutical exports; calls for clear roadmap from China


    This translates to a robust approach to regulatory compliance for manufacturing facilities, the report added.


    "Domestic pharmaceutical companies need to step up their regulatory compliance to secure impeccable reputation as reliable suppliers and provide the targeted return on the ongoing and planned research and development and capital investments over the next decade," the report noted.


    From the second half of 2017, the industry has been witnessing a resolution of key manufacturing facilities of large manufacturers under warning letters and import alerts with an average period of 24 to 36 months after regulatory restriction, it noted.


    "While this is encouraging, a reduction in resolution times and limited repeat observations would indicate regulatory discipline re-tuning to the industry," it warned.


    Input quality risks stemming from high dependence on Chinese players has been an emerging concern in FY19, leading to product recalls initiated by major players. Therefore, securing a supply chain is likely to emerge as a top priority as several complex generics and innovative pipelines will hit the markets in the next decade, it said.


    The credit profile and return ratios of companies with regulatory deviations have been adversely impacted attributed to remediation cost and restricted market presence.


    "Domestic companies are likely to spend higher capex for upgrading infrastructure for regulatory compliance over FY20-FY30," the report said and expects domestic formulators' product portfolio mix to undergo a structural shift next decade due to moving up the value chain and the resultant doubling of R&D spends.


    Read Also: Pharmaceutical exports rise 11 percent to USD 19.2 billion in 2018-19

    capexChinese marketdomestic pharma coFY19FY20FY30generic drugsindia ratingsindian pharma companiespharmaPharma companiespharma newspharma news indiapharmaceutical companies
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok